Related Experiment Video
Updated: May 9, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Anti-hepatitis C virus drugs in development
Esperance A K Schaefer1, Raymond T Chung
1Massachusetts General Hospital, Department of Medicine, Gastrointestinal Unit, Boston, USA. eschaefer@partners.org
New hepatitis C virus (HCV) therapies are emerging, targeting viral proteins and host factors. These advancements promise highly effective and well-tolerated treatments, potentially reducing reliance on interferon.
Area of Science:
- Virology
- Hepatology
- Pharmacology
Background:
- Robust cell culture models have advanced hepatitis C virus (HCV) research.
- Understanding the HCV life cycle facilitates targeted drug development.
- Early therapies focused on NS3/4A serine protease inhibitors.
Purpose of the Study:
- To review the development of novel therapeutic agents for hepatitis C.
- To highlight emerging drugs targeting viral replication and host factors.
- To discuss the future of HCV treatment.
Main Methods:
- Review of current research and clinical development of HCV therapeutics.
- Analysis of drug classes targeting viral proteins (protease, polymerase, NS5A).
- Evaluation of host-directed antivirals and alternative interferons.
Main Results:
- Multiple drug classes are in advanced clinical development, including new protease, NS5B polymerase, and NS5A inhibitors.
- Host-directed antivirals like cyclophilin inhibitors show promise.
- Interferon-lambda1 (interleukin-29) offers a potentially better-tolerated alternative to traditional interferons.
Conclusions:
- Emerging HCV therapies are poised to offer highly effective and well-tolerated treatment options.
- Future therapies are likely to be interferon-sparing.
- Significant progress in HCV drug development is expected in the coming years.
More Related Videos
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Retrovirus Life Cycles
Pharmacogenomics: Identification of New Drug Targets
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction